Review

Published on 08 Nov 2024

Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

in Thoracic Oncology

Ziyang Jiang
Zhihan Gu
Xiaomin Yu
Tao Cheng
Bofu Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1447678

272 views

Systematic Review

Published on 07 Nov 2024

Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis

in Thoracic Oncology

Yihao Liu
Liangyu Yang
Zhixuan Duan
Qian Cheng
Minghui Liu
HongBing Zhang
HongLin Zhao

Frontiers in Oncology

doi 10.3389/fonc.2024.1444312

336 views

Case Report

Published on 07 Nov 2024

Case report: Pulmonary Ewing sarcoma disguised as non-small cell lung cancer

in Thoracic Oncology

Mary E. Carter
Alessia Benegiamo-Chilla
Linus D. Kloker
Nikolas Paulsen
Vlatko Potkrajcic
Frank Paulsen
Attila Nemeth
Volker Steger
Martin Schulze
Saskia Biskup

Frontiers in Oncology

doi 10.3389/fonc.2024.1449119

376 views

Case Report

Published on 07 Nov 2024

Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression

in Thoracic Oncology

Shuo Wu
Changhong Dong
Chenxi Hu

Frontiers in Oncology

doi 10.3389/fonc.2024.1437260

285 views

Original Research

Accepted on 06 Nov 2024

Application of Disitamab vedotin in the Multiline Treatment of EGFR Mutation-Positive Lung Adenocarcinoma with Her-2 Overexpression

in Thoracic Oncology

Meiling Lan
Tianyun Wang
Diexiao Luo
Yan Chen
Wei Liang
Rui Kong
Qichao Xie

Frontiers in Oncology

doi 10.3389/fonc.2024.1472545

Original Research

Accepted on 05 Nov 2024

Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

in Thoracic Oncology

Zachary D Wallen
Mary Nesline
Marni Tierno
Alison Roos
Erica Schnettler
Hatim Husain
Pratheesh Sathyan
Brian Caveney
Marcia Eisenberg
Eric A Severson

Frontiers in Oncology

doi 10.3389/fonc.2024.1473327

Perspective

Accepted on 05 Nov 2024

Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC

in Thoracic Oncology

Michelle Shiller
Melissa Johnson
Robert Auber
Sandip Pravin Patel

Frontiers in Oncology

doi 10.3389/fonc.2024.1459737

Original Research

Accepted on 04 Nov 2024

The Diagnostic Efficacy of Seven Autoantibodies in Early Detection of Ground-glass Nodular Lung Adenocarcinoma

in Thoracic Oncology

Hua Guo
Wei Zhao
Chunsun Li
Zhen Wu
Ling Yu
Miaoyu Wang
Yuanhui Wei
Zirui Wang
Shangshu Liu
Yue Yin

Frontiers in Oncology

doi 10.3389/fonc.2024.1499140

Original Research

Published on 04 Nov 2024

The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis

in Thoracic Oncology

Zhenghua Cao
Shengkun Zhao
Tong Wu
Huan Ding
Zhiyu Tian
Feng Sun
Zhuo Feng

Frontiers in Oncology

doi 10.3389/fonc.2024.1438851

442 views

Editorial

Published on 04 Nov 2024

Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer

in Thoracic Oncology

Francesco Cortiula
Aakash Desai
Jessica Menis
Andrea R. Filippi

Frontiers in Oncology

doi 10.3389/fonc.2024.1503613

301 views

Original Research

Published on 04 Nov 2024

Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study

in Thoracic Oncology

Anna Tanaka
Shuhei Teranishi
Yukihito Kajita
Tomofumi Hirose
Ayami Kaneko
Yu Sairenji
Hidetoshi Kawashima
Kentaro Yumoto
Toshinori Tsukahara
Kenji Miura

Frontiers in Oncology

doi 10.3389/fonc.2024.1400277

487 views

Mini Review

Published on 01 Nov 2024

Exercise’s impact on lung cancer molecular mechanisms: a current overview

in Thoracic Oncology

Annamaria Mancini
Francesca Maria Orlandella
Daniela Vitucci
Neila Luciano
Andreina Alfieri
Stefania Orrù
Giuliana Salvatore
Pasqualina Buono

Frontiers in Oncology

doi 10.3389/fonc.2024.1479454

394 views

Case Report

Published on 01 Nov 2024

Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports

in Thoracic Oncology

Yuan Zeng
Qiang Zeng
Bin Yang

Frontiers in Oncology

doi 10.3389/fonc.2024.1390523

470 views

Editorial

Published on 31 Oct 2024

Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC

in Thoracic Oncology

Paola Ulivi

Frontiers in Oncology

doi 10.3389/fonc.2024.1506160

409 views

Case Report

Published on 31 Oct 2024

Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory

in Thoracic Oncology

Kyle C. Strickland
Mary K. Nesline
Rebecca A. Previs
Heidi Ko
Maureen Cooper
Jennifer R. Rushton
Zachary D. Wallen
Sarabjot Pabla
Jeffrey M. Conroy
Mark Sausen

Frontiers in Oncology

doi 10.3389/fonc.2024.1445668

567 views

Original Research

Published on 30 Oct 2024

The value of multiple diffusion metrics based on whole-lesion histogram analysis in evaluating the subtypes and proliferation status of non-small cell lung cancer

in Thoracic Oncology

Yao Chen
Hong Yang
Yuan Qin
Chuanjiang Guan
Wenbing Zeng
Yong Luo

Frontiers in Oncology

doi 10.3389/fonc.2024.1434326

346 views

Navigation group

Articles

Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

Efficacy and safety of Toliparibumab for the treatment of non-small cell lung cancer: a systematic review and meta-analysis

Case report: Pulmonary Ewing sarcoma disguised as non-small cell lung cancer

Case report: Combination therapy of envafolimab with endostar for advanced non-small cell lung cancer with low PD-L1 expression

Application of Disitamab vedotin in the Multiline Treatment of EGFR Mutation-Positive Lung Adenocarcinoma with Her-2 Overexpression

Genomic profiling of NSCLC tumors with the TruSight Oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC

The Diagnostic Efficacy of Seven Autoantibodies in Early Detection of Ground-glass Nodular Lung Adenocarcinoma

The causal nexus between diverse smoking statuses, potential therapeutic targets, and NSCLC: insights from Mendelian randomization and mediation analysis

Editorial: Innovative strategies and new insights for the treatment of stage III non-small cell lung cancer

Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study

Exercise’s impact on lung cancer molecular mechanisms: a current overview

Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports

Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC

Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory

The value of multiple diffusion metrics based on whole-lesion histogram analysis in evaluating the subtypes and proliferation status of non-small cell lung cancer